Amniotics Investor Relations Material
Latest events
Q2 2024
20 Aug, 2024
Q4 2023
22 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Amniotics
Access all reports
Amniotics AB is a Swedish biotechnology company focused on developing stem cell-based therapeutics for severe, life-threatening diseases. The company specializes in mesenchymal stem cells (MSCs) derived from amniotic fluid, which are used to create targeted treatments for various conditions. Amniotics has developed several product candidates, including PulmoStem, aimed at treating lung diseases, CogniStem for central nervous system disorders, NephroStem for kidney conditions, and CutiStem for skin therapies. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
AMNI
Country
🇸🇪 Sweden